Somewhat Favorable Media Coverage Somewhat Unlikely to Affect MabVax Therapeutics Holdings (NASDAQ:MBVX) Share Price

News coverage about MabVax Therapeutics Holdings (NASDAQ:MBVX) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MabVax Therapeutics Holdings earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.6563464562303 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Shares of MabVax Therapeutics Holdings (MBVX) opened at 0.50 on Friday. The firm’s market capitalization is $5.28 million. MabVax Therapeutics Holdings has a 52-week low of $0.43 and a 52-week high of $6.05. The stock’s 50 day moving average is $0.86 and its 200 day moving average is $1.86.

MabVax Therapeutics Holdings (NASDAQ:MBVX) last released its quarterly earnings data on Monday, August 14th. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.69) by $0.78. On average, equities research analysts forecast that MabVax Therapeutics Holdings will post ($2.91) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by BBNS and is owned by of BBNS. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/mabvax-therapeutics-holdings-nasdaqmbvx-receives-daily-media-sentiment-score-of-0-14-updated/1408458.html.

MabVax Therapeutics Holdings Company Profile

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Receive News & Ratings for MabVax Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics Holdings Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.